Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats

Stroke

Volumn 41, Issue 2, 2010, Pages 368-374

  Hasegawa, Yu ^a   Suzuki, Hidenori ^a   Sozen, Takumi ^a   Rolland, William ^a   Zhang, John H ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cerebral ischemia; FTY720; Sphingosine 1 phosphate receptor 1

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; CASPASE 3; FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE RECEPTOR; APOPTOSIS REGULATORY PROTEIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NEUROPROTECTIVE AGENT; OXADIAZOLE DERIVATIVE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG ANTAGONISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NERVE CELL; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; NERVE DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STROKE; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MAP KINASE SIGNALING SYSTEM; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXADIAZOLES; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STROKE; THIOPHENES; TREATMENT OUTCOME;

EID: 77449106966     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.568899     Document Type: Article

References (27)

1. Singh IN, Hall ED. Multifaceted roles of sphingosine-1-phosphate: how does this bioactive sphingolipid fit with acute neurological injury? J Neurosci Res. 2008;86:1419-1433.
2. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
3. Yagi H, Kamba R, Chiba K, Soga H, Yaguchi K, Nakamura M, Itoh T. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol. 2000;30:1435-1444.
4. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation. 2001;72: 764-769.
5. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, Antel JP, Soliven B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia. 2007;55:1656-1667.
6. Troncoso P, Ortíz M, Martínez L, Kahan BD. FTY 720 prevents ischemic reperfusion damage in rat kidneys. Transplant Proc. 2001;33:857-859.
7. Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Lassman C, Ke B, Coito AJ, Ma J, Brinkmann V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. FTY720 pretreatment reduces warm hepatic ischemia reper-fusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant. 2002;2:843-849.
8. Hasegawa Y, Hamada J, Morioka M, Yano S, Kawano T, Kai Y, Fukunaga K, Ushio Y. Neuroprotective effect of postischemic administration of sodium orthovanadate in rats with transient middle cérébral artery occlusion. J Cereb Blood Flow Metab. 2003;23:1040-1051.
9. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cérébral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
10. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, Lynch KR, Okusa MD. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290:F1516-F1524.
11. Landeen LK, Dederko DA, Kondo CS, Hu BS, Aroonsakool N, Haga JH, Giles WR. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H736-H749.
12. Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cérébral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke. 1995;26:636-642.
13. Tsubokawa T, Solaroglu I, Yatsushige H, Cahill J, Yata K, Zhang JH. Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cérébral ischemia in rats. Stroke. 2006;37:1888-1894.
14. Sun Y, Zhou C, Polk P, Nanda A, Zhang JH. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab. 2004;24:259-270.
15. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117:77-93.
16. Chae SS, Proia RL, Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat. 2004;73:141-150.
17. Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta. 2002; 1582:72-80.
18. Sawe N, Steinberg G, Zhao H. Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J Neurosci Res. 2008;86:1659-1669.
19. Matsuda S, Minowa A, Suzuki S, Koyasu S. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol. 1999;162:3321-3326.
20. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005;108: 308-319.
21. Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoe S, Hoshino Y, Chiba K. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200-205.
22. Suzuki S, Li XK, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology. 1996;89:518-523.
23. Kimura A, Ohmori T, Kashiwakura Y, Ohkawa R, Madoiwa S, Mimuro J, Shimazaki K, Hoshino Y, Yatomi Y, Sakata Y. Antagonism of sphin-gosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke. 2008;39:3411-3417.
24. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, Jusko WJ. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4- octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos. 2006;34: 1480-1487.
25. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4:1019-1025.
26. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140.
27. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mul-gaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2005;79:1553-1560.